jak2v617f inhibitor incb160058
jak2v617f inhibitor incb160058: 2 clinical trials tracked.
jak2v617f inhibitor incb160058 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about jak2v617f inhibitor incb160058, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Dose-Escalation, Drug-Interaction, and Food-Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participants
Primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs)